A recombinant Escherichia coli producing active heparan sulfate N-deacetyl / N-sulfotransferase and its construction method
By constructing recombinant Escherichia coli and fusing and mutating heparan sulfate N-deacetyl/N-sulfotransferase, the activity expression limitation of heparan sulfate N-deacetylase in Escherichia coli was solved, achieving efficient synthesis of heparan sulfate and heparin and reducing production costs.
Patent Information
- Application Number
- CN202510597461.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-05-09
- Publication Date
- 2026-11-10
AI Technical Summary
In the prior art, the activity expression of heparan sulfate N-deacetyl/N-sulfotransferase in Escherichia coli is limited, which restricts the de novo synthesis of heparan sulfate and heparin in prokaryotic microorganisms such as Escherichia coli and increases the cost of total enzymatic synthesis.
Recombinant Escherichia coli was constructed by fusing zebrafish-derived or human-derived heparin sulfate N-deacetylase and heparin sulfate N-sulfotransferase, combining site-directed mutagenesis and combinatorial mutagenesis to achieve active expression, and expressed using the pET32a vector to form an active heparin sulfate N-deacetyl/N-sulfotransferase suitable for Escherichia coli.
This method achieves efficient active expression in Escherichia coli, improves the sulfonation conversion rate of N-sulfonated heparin precursor, promotes the synthesis of heparan sulfate, heparin, low molecular weight heparin and heparin oligosaccharides, and reduces production costs.
Smart Images

Figure CN123063366A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to a recombinant Escherichia coli that produces active heparan sulfate N-deacetyl / N-sulfotransferase and its construction method, belonging to the field of bioengineering technology. Background Technology
[0002] Heparan sulfate (HS) / Heparin (HP) is a class of glycosaminoglycans with complex sulfonation modifications that are widely used in clinical treatment due to its various biological activities, including anticoagulation and anti-inflammation. Heparan sulfate and heparin have similar glycan structures, but heparan sulfate has a lower sulfonation level and more diverse sulfonation modification patterns compared to heparin. Heparin, on the other hand, has a higher sulfonation modification level and is considered to be one of the most structurally complex glycosaminoglycans.
[0003] To avoid the risks associated with animal-derived heparin sulfate and heparin, such as supply chain limitations related to animal raw materials, contamination by other impurities or allergens, and residual animal viruses, enzymatic synthesis and de novo microbial synthesis have been developed as new alternative production methods. However, the synthesis of heparin sulfate and heparin requires sequential modification by heparin sulfate N-deacetylase / N-sulfotransferase, C5-epomerase, 2-O-sulfotransferase, 6-O-sulfotransferase, and 3-O-sulfotransferase. The modification product of the first step, heparin sulfate N-deacetylase / N-sulfotransferase, not only serves as a substrate for subsequent modifying enzymes but also significantly influences the overall sulfonation modification level and biological activity of heparin sulfate and heparin. However, due to the limitation of N-deacetylase expression, the activity of heparan sulfate N-deacetyl / N-sulfotransferase is mainly limited to eukaryotic expression systems such as yeast cells and mammalian cells with long growth cycles. In contrast, other heparin-modifying enzymes have achieved active expression in Escherichia coli. Therefore, heparan sulfate N-deacetyl / N-sulfotransferase severely limits the de novo synthesis of heparan sulfate and heparin in prokaryotic microorganisms such as Escherichia coli, and also increases the cost of in vitro whole-enzyme synthesis.
[0004] Therefore, constructing a heparan sulfate N-deacetyl / N-sulfotransferase that can be actively expressed in an Escherichia coli expression system is of great significance and application value for the subsequent de novo synthesis or holoenzymatic synthesis of heparan sulfate, heparin and other related products using prokaryotic microorganisms such as Escherichia coli. Summary of the Invention
[0005] To address the shortcomings of the prior art, this invention provides a recombinant Escherichia coli that produces active heparan sulfate N-deacetyl / N-sulfotransferase and its construction method, aiming to solve the technical problem of how to enhance the activity expression of heparan sulfate N-deacetyl / N-sulfotransferase in Escherichia coli.
[0006] The first technical solution provided by the present invention is a heparin sulfate N-deacetyl / N-sulfotransferase, wherein the heparin sulfate N-deacetyl / N-sulfotransferase is formed by linking heparin sulfate N-deacetylase and heparin sulfate N-sulfotransferase.
[0007] In some embodiments, the heparan sulfate N-deacetylase is amino acid 41-606 of zebrafish-derived heparan sulfate N-deacetylase (DrNDase, NCBI accession number NP_001311384.1), amino acid 99-657 of pendulum shrimp-derived heparan sulfate N-deacetylase (PvNDase, NCBI accession number XP_027233623.1), or amino acid 40-602 of human-derived heparan sulfate N-deacetylase (HsNDase, NCBI accession number NP_001534.1).
[0008] In some embodiments, the heparin sulfate N-sulfotransferase is amino acid 607-886 of the zebrafish-derived heparin sulfate N-sulfotransferase sequence (Danio rerio heparan sulfate N-sulfotransferase, DrNST, NCBI accession number NP_001311384.1); or it is human heparin sulfate N-sulfotransferase Mut02 with an amino acid sequence as shown in SEQ ID NO.7, wherein the human heparin sulfate N-sulfotransferase Mut02 is derived from amino acid 603-882 of the human heparin sulfate N-sulfotransferase sequence (Homo sapiens heparan sulfate N-sulfotransferase, HsNST, NCBI accession number NP_001534.1); the construction method of human heparin sulfate N-sulfotransferase Mut02 (HsNST Mut02) can be found in the literature: Improvement of the stability and catalytic efficiency of heparan sulfate N-sulfotransferase for preparing N-sulfated heparosan. J Ind Microbiol Biotechnol. 2023 Feb17; 50(1):kuad012..
[0009] In some embodiments, the N-terminus of the heparan sulfate N-deacetylase is fused with a maltose-binding protein using a G4S linker peptide.
[0010] In some embodiments, the C-terminus of the heparan sulfate N-deacetylase is fused with heparan sulfate N-sulfotransferase.
[0011] In some embodiments, there is no linker sequence between the heparan sulfate N-deacetylase and the heparan sulfate N-sulfotransferase, or an EAAAK, G4S, or G6 linker peptide is used.
[0012] In some embodiments, the amino acid sequence of the heparan sulfate N-deacetyl / N-sulfotransferase is as shown in SEQ ID NO.1.
[0013] The second technical solution provided by this invention is a mutant protein of heparan sulfate N-deacetyl / N-sulfotransferase. The mutant protein is based on heparan sulfate N-deacetylase and heparan sulfate N-sulfotransferase, whose amino acid sequences are shown in SEQ ID NO.1, as parent proteins, and one or more of the following mutations are performed on the parent proteins:
[0014] (1) The heparin sulfate N-deacetyl / N-sulfotransferase mutant protein was obtained by replacing the aspartic acid (D) residue at position 110 with the glutamate (E) residue;
[0015] (2) The mutant protein of heparan sulfate N-deacetyl / N-sulfotransferase obtained by replacing the isoleucine (I) residue at position 111 with a valine (V) residue;
[0016] (3) The mutant protein of heparan sulfate N-deacetyl / N-sulfotransferase was obtained by replacing the glutamine (Q) residue at position 189 with a leucine (L) residue;
[0017] (4) The mutant protein of heparan sulfate N-deacetyl / N-sulfotransferase was obtained by replacing the phenylalanine (F) residue at position 219 with histidine (H) residue;
[0018] (5) The mutant protein of heparan sulfate N-deacetyl / N-sulfotransferase obtained by replacing the arginine (R) residue at position 224 with a glycine (G) residue;
[0019] (6) The mutant protein of heparan sulfate N-deacetyl / N-sulfotransferase obtained by replacing the glutamate (E) residue at position 227 with a leucine (L) residue;
[0020] (7) The mutant protein of heparan sulfate N-deacetyl / N-sulfotransferase obtained by replacing the threonine (T) residue at position 244 with a serine (S) residue;
[0021] (8) The mutant protein of heparan sulfate N-deacetyl / N-sulfotransferase obtained by replacing the arginine (R) residue at position 255 with a glutamine (Q) residue;
[0022] (9) The mutant protein of heparan sulfate N-deacetyl / N-sulfotransferase was obtained by replacing the serine (S) residue at position 260 with the isoleucine (I) residue;
[0023] (10) The mutant protein of heparan sulfate N-deacetyl / N-sulfotransferase obtained by replacing the alanine (A) residue at position 269 with a serine (S) residue;
[0024] (11) The heparin sulfate N-deacetyl / N-sulfotransferase mutant protein was obtained by replacing the asparagine (N) residue at position 351 with a threonine (T) residue;
[0025] (12) The mutant protein of heparan sulfate N-deacetyl / N-sulfotransferase obtained by replacing the alanine (A) residue at position 369 with a threonine (T) residue;
[0026] (13) The mutant protein of heparan sulfate N-deacetyl / N-sulfotransferase obtained by replacing the serine (S) residue at position 385 with a valine (V) residue;
[0027] (14) The mutant protein of heparan sulfate N-deacetyl / N-sulfotransferase obtained by replacing the isoleucine (I) residue at position 443 with a valine (V) residue;
[0028] (15) The mutant protein of heparan sulfate N-deacetyl / N-sulfotransferase obtained by replacing the valine (V) residue at position 478 with the isoleucine (I) residue;
[0029] (16) The heparin sulfate N-deacetyl / N-sulfotransferase mutant protein was obtained by replacing the serine (S) residue at position 480 with an asparagine (N) residue;
[0030] (17) The mutant protein of heparan sulfate N-deacetyl / N-sulfotransferase obtained by replacing the serine (S) residue at position 483 with a methionine (M) residue;
[0031] (18) The mutant protein of heparan sulfate N-deacetyl / N-sulfotransferase obtained by replacing the glycine (G) residue at position 505 with a serine (S) residue;
[0032] (19) The mutant protein of heparan sulfate N-deacetyl / N-sulfotransferase obtained by replacing the leucine (L) residue at position 512 with a serine (S) residue;
[0033] (20) The heparin sulfate N-deacetyl / N-sulfotransferase mutant protein was obtained by replacing the serine (S) residue at position 561 with an arginine (R) residue;
[0034] (21) The mutant protein of heparan sulfate N-deacetyl / N-sulfotransferase obtained by replacing the isoleucine (I) residue at position 577 with a leucine (L) residue;
[0035] (22) The heparin sulfate N-deacetyl / N-sulfotransferase mutant protein was obtained by replacing the proline (P) residue at position 579 with a serine (S) residue;
[0036] (23) The heparin sulfate N-deacetyl / N-sulfotransferase mutant protein obtained by replacing the arginine (R) residue at position 582 with a valine (V) or lysine (K) residue;
[0037] (24) The mutant protein of heparan sulfate N-deacetyl / N-sulfotransferase obtained by replacing histidine (H) residue at position 585 with leucine (L) residue;
[0038] (25) The heparin sulfate N-deacetyl / N-sulfotransferase mutant protein was obtained by replacing the aspartic acid (D) residue at position 588 with an asparagine (N) residue;
[0039] (26) The mutant protein of heparan sulfate N-deacetyl / N-sulfotransferase was obtained by replacing the glutamate (E) residue at position 591 with an alanine (A) residue.
[0040] Preferably, the mutant protein is a parent protein consisting of heparan sulfate N-deacetylase and heparan sulfate N-sulfotransferase with amino acid sequences as shown in SEQ ID NO.1, and the parent protein is subjected to any of the following combination mutations:
[0041] (a) The phenylalanine (F) residue at position 219 was replaced with a histidine (H) residue, and the serine (S) residue at position 480 was replaced with asparagine (N) to obtain the combined spike protein F219H / S480N;
[0042] (b) The phenylalanine (F) residue at position 219 is replaced with a histidine (H) residue, the serine (S) residue at position 480 is replaced with asparagine (N), and the arginine (R) residue at position 582 is replaced with a valine (V) or lysine (K) residue to obtain the combined spike protein F219H / S480N / R582V or F219H / S480N / R582K.
[0043] The third technical solution provided by the present invention is a gene encoding the heparin sulfate N-deacetyl / N-sulfotransferase described in the first technical solution or the mutant protein described in the second technical solution.
[0044] The fourth technical solution provided by this invention is a recombinant plasmid carrying the gene described in the third technical solution.
[0045] In some implementations, the recombinant plasmid is expressed using the pET32a vector.
[0046] The fifth technical solution provided by the present invention is a recombinant cell expressing the heparin sulfate N-deacetyl / N-sulfotransferase described in the first technical solution or the mutant protein described in the second technical solution, or containing the gene described in the third technical solution, or carrying the recombinant plasmid described in the fourth technical solution.
[0047] In some embodiments, the recombinant cells include microbial cells, plant cells, and animal cells.
[0048] In some embodiments, the microbial cells include fungi and bacteria.
[0049] In some embodiments, the recombinant cells use Escherichia coli as a host.
[0050] The sixth technical solution provided by the present invention is a recombinant Escherichia coli, wherein the recombinant Escherichia coli uses pET32a vector as an expression vector to express the heparan sulfate N-deacetylase and heparan sulfate N-sulfotransferase described in the first technical solution or the mutant protein described in the second technical solution.
[0051] This invention provides a method for producing heparin sulfate N-deacetylase or heparin sulfate N-deacetyl / N-sulfotransferase. Specifically, the method involves fermentation production using a host cell containing the gene encoding the mutant of heparin sulfate N-deacetylase or heparin sulfate N-deacetyl / N-sulfotransferase. The host cell can be a microorganism, including but not limited to Escherichia coli, and the cell can be any biological cell capable of synthesizing heparin sulfate N-deacetylase or heparin sulfate N-deacetyl / N-sulfotransferase.
[0052] The seventh technical solution provided by the present invention is a method for preparing N-sulfonated heparin precursor by enzyme catalysis. The method uses heparin precursor as substrate and uses the N-deacetyl / N-sulfotransferase of heparan sulfate described in the first technical solution or the mutant protein described in the second technical solution as catalyst to form a catalytic system to synthesize N-sulfonated heparin precursor.
[0053] In some embodiments, the heparin sulfate N-deacetyl / N-sulfotransferase enzyme solution formed from the protein with the above-described heparin sulfate N-deacetyl / N-sulfotransferase function is catalyzed.
[0054] In some embodiments, the enzyme catalytic system includes a substrate, such as a heparin precursor, as well as metal ions and coenzymes required for the conversion.
[0055] In some embodiments, the catalytic reaction system contains an enzyme solution of heparan sulfate N-deacetyl / N-sulfotransferase, a heparin precursor, 3'-adenosine-5'-phosphate sulfate (PAPS), glycerol, and CaCl2; or, the reaction system contains a bifunctional N-deacetyl / N-sulfotransferase enzyme solution, a heparin precursor, p-nitrobenzenesulfonic acid (PNPS), 3',5'-adenosine diphosphate (PAP), arylsulfotransferase (AST IV), glycerol, and CaCl2.
[0056] In some embodiments, the catalytic reaction system contains an enzyme solution of heparan sulfate N-deacetyl / N-sulfotransferase, 200-2000 μg / mL heparin precursor, 1-10 mM 3'-adenosine-5'-phosphate sulfate (PAPS), 10-50% (v / v) glycerol, and 10-30 mM CaCl2; or, the reaction system contains a bifunctional N-deacetyl / N-sulfotransferase enzyme solution, 200-2000 μg / mL heparin precursor, 5-50 mM p-nitrobenzenesulfonic acid (PNPS), 0.1-0.5 mM 3',5'-adenosine diphosphate (PAP), 2-5 mg / mL arylsulfotransferase (AST IV), 10-50% (v / v) glycerol, and 10-30 mM CaCl2.
[0057] The eighth technical solution provided by the present invention is the application of the heparan sulfate N-deacetyl / N-sulfotransferase described in the first technical solution or the mutant protein described in the second technical solution in the synthesis of heparan sulfate, heparin and low molecular weight heparin and heparin oligosaccharides.
[0058] The technical effects of this invention are as follows:
[0059] This invention first screened for active heparin sulfate N-deacetylase, achieving active expression of the N-deacetylase in prokaryotic microbial hosts. Further, it combined the active heparin sulfate N-deacetylase with heparin sulfate N-sulfotransferase, providing an artificial heparin sulfate N-deacetyl / N-sulfotransferase suitable for active expression in *E. coli*. Through site-directed mutagenesis and combinatorial mutagenesis, a combinatorial mutant was obtained, achieving an enzyme activity of 2812 U / mg, which can increase the sulfonation conversion rate of 2000 mg / L N-sulfonated heparin precursor to over 60%. This is of great significance for the de novo synthesis and related research of heparin sulfate, heparin, low molecular weight heparin, and heparin oligosaccharides using prokaryotic expression hosts such as *E. coli*. Attached Figure Description
[0060] Figure 1 a is a schematic diagram of the catalytic pathway of N-deacetylase; Figure 1 b is a diagram identifying the catalytic products of N-deacetylases from different sources.
[0061] Figure 2 This is a comparison of the enzyme activities of artificial heparan sulfate N-deacetyl / N-sulfotransferases linked in different ways.
[0062] Figure 3 a) is an enzyme activity analysis of wild-type and single-point mutant N-deacetyl / N-sulfotransferases of artificial heparan sulfate. Figure 3 b is the enzyme activity analysis of the multi-point mutant.
[0063] Figure 4 This study analyzed the specific enzyme activity of wild-type and dominant mutant N-deacetyl / N-sulfotransferase of artificial heparan sulfate.
[0064] Figure 5 a is a schematic diagram of the catalytic pathway of the artificial heparan sulfate N-deacetyl / N-sulfotransferase combined mutant; Figure 5 b represents the N-sulfonation level analysis of the catalytic product. Detailed Implementation
[0065] The preferred embodiments of the present invention are described below. It should be understood that the embodiments are for better explanation of the present invention and are not intended to limit the present invention.
[0066] Test method:
[0067] 1. Method for determining the enzyme activity of heparan sulfate N-deacetyl / N-sulfotransferase: At 37℃, add 50mM p-nitrobenzenesulfonic acid (PNPS), 0.5mM 3',5'-adenosine diphosphate (PAP), 2mg arylsulfotransferase (AST IV), 10% (v / v) glycerol, 10mM CaCl2, 1mg heparin precursor, and an appropriate amount of crude or purified heparan sulfate N-deacetyl / N-sulfotransferase enzyme solution to the reaction system. Adjust the volume to 1.0mL with a 20mM Tris-HCl buffer (pH 7.5), and incubate at 37℃ for 12h. Then, measure the activity of the experimental group and the blank control group (A). 400 The difference in absorbance. Enzyme activity is defined as the amount of enzyme required per hour to convert 1 μM PNP.
[0068] 2. Detection of Catalytic Products: Ultra-high performance liquid chromatography (UHPLC) tandem quadrupole time-of-flight mass spectrometry (TOF-MS) was used for identification and analysis. The parameters were as follows: Oligosaccharide samples were analyzed on an UHPLC system equipped with a CSH C18 column (1.7 μm, 2.1 mm × 50 mm) and a PDA detector. The detection temperature was 45 °C, mobile phase A was 0.1 mol / L formic acid, and mobile phase B was acetonitrile. ESI-MS spectra were obtained using a MALDI SYNAPT Q-TOF MS system in negative ionization mode. The operating program was: cone voltage 20 V, detection voltage 2.0 kV, capillary voltage 3.0 kV, source temperature 100 °C, and desolventizing temperature 400 °C. The mass range of the ESIMS spectra was 50–2000 m / z, and the collision energy was 6 / 20 V.
[0069] Raw materials used in the examples:
[0070] (I) Strains
[0071] The strains Escherichia coli Rosetta (DE3) and E. coli JM019 were purchased from Novagen.
[0072] (II) Culture medium
[0073] LB medium (g / L): yeast extract 5.0, peptone 10.0, NaCl 10.0. Solid medium contains 20.0 g / L agar powder. Resistance medium is supplemented with 100 mg / L ampicillin and 50 mg / L chloramphenicol.
[0074] TB medium (g / L): yeast extract 24.0; peptone 12.0; glycerol 5.0; K2HPO4·3H2O 16.43; KH2PO4 2.31. The resistance medium was supplemented with 100 mg / L ampicillin and 50 mg / L chloramphenicol.
[0075] Example 1: Expression and catalysis of heparan sulfate N-deacetylase
[0076] Using standard PCR amplification systems and procedures, the pET32a vector fragment was amplified using vector-F / vector-R primers. Maltose-binding protein (MBP) fragments were amplified from the *E. coli* genome using MBP-F / MBP-G4S-R primers, with nucleotide sequences shown in SEQ ID NO.2. Different synthetically produced heparan sulfate N-deacetylase genes (optimized according to *E. coli* codon preferences, nucleotide sequences shown in SEQ ID NO.3–5) were amplified using DrNDase-F / R, HsNDase-F / R, and PvNDase-F / R, respectively. Ligation was performed using seamless cloning to obtain multiple recombinant plasmids: pET32a-MBP-DrNDase, pET32a-MBP-HsNDase, and pET32a-MBP-PvNDase. In each case, maltose-binding protein MBP was ligated to the N-terminus of the target enzyme via a G4S linker sequence, and a 6×His tag was fused to the C-terminus of the target enzyme. Recombinant plasmids pET32a-MBP-DrNDase, pET32a-MBP-HsNDase, and pET32a-MBP-PvNDase were transformed into E. coli Rosetta(DE3). Transformants were obtained after culturing. Transformants that were verified by sequencing were considered positive transformants, which were recombinant E. coli strains expressing heparan sulfate N-deacetylase.
[0077] A single colony of recombinant *E. coli* was picked and seeded in LB medium. This seed culture was then transferred to TB medium at a 1% inoculum and cultured at 37°C and 220 rpm for 2 hours. Induction with 0.5 mM IPTG was then performed, followed by further culture at 25°C for 16-20 hours. The fermentation broth was centrifuged at 4°C (6000 rpm, 10 min), the supernatant was discarded, and the cells were resuspended 2-3 times in 20 mM Tris-HCl buffer. The cells were then disrupted using an ultrasonic cell disruptor and centrifuged at 12000 rpm for 20 min to obtain the crude enzyme solution. The crude enzyme solution was filtered through a 0.22 μm filter membrane, and the supernatant was loaded onto a nickel column using an AKTA purification system. Elution was performed using an elution buffer containing 20 mM Tris-HCl buffer, 500 mM imidazole, and 500 mM NaCl to obtain the purified enzyme solution, which was used to catalyze the heparin precursor.
[0078] The catalytic reaction was carried out at 37°C. 0.5-2 mg N-deacetylase solution, 1 mg heparin precursor, 10 mM CaCl2, and a 20 mM Tris-HCl buffer (pH 7.5) were added to the reaction system, bringing the volume to 0.5 mL. The mixture was incubated at 37°C for 12-24 h. After the reaction was complete, 50 mM PNPS, 0.5 mM PAP, 2 mg AST IV, 10% (v / v) glycerol, and 2 mg N-sulfotransferase were added to the reaction system, or 4 mM PAPS, 10% (v / v) glycerol, and 2 mg N-sulfotransferase were added. The volume was brought to 1.0 mL with a 20 mM Tris-HCl buffer (pH 7.5), and the mixture was incubated at 37°C for 12 h. After the reaction was completed, 1 mg of heparin lyase was added to the reaction system and reacted at 37 °C to fully degrade it into disaccharides. The lysis products were filtered through a 0.22 μm filter membrane and identified and analyzed by ultra-high performance liquid chromatography-tandem quadrupole time-of-flight mass spectrometry.
[0079] Table 1 Primer construction table
[0080]
[0081] The results are as follows Figure 1 a, Figure 1 As shown in b, the target disaccharide is present in the catalytic products of PvNDase and DrNDase, and the target peak of DrNDase is more obvious than that of PvNDase.
[0082] Example 2: Construction and catalysis of artificial heparan sulfate N-deacetyl / N-sulfotransferase
[0083] Using standard PCR amplification systems and procedures, plasmids (pET32a-MBP-DrNDase, pET32a-MBP-PvNDase) carrying the active N-deacetylase gene from Example 1 were used as vectors. A seamless cloning technique was used to ligate the N-sulfonyltransferase gene (nucleotide sequence as shown in SEQ ID NO. 6) to the C-terminus of the N-deacetylase gene. The N-deacetylase gene and N-sulfonyltransferase gene were ligated using adapter sequences such as EK (EAAAK corresponding to the nucleotide sequence GAAGCGGCGGCGAAA), G4S (GGGGS corresponding to the nucleotide sequence GGCGGTGGTGGTAGC), and G6 (GGGGGG corresponding to the nucleotide sequence GGTGGCGGTGGCGGT) or without adapter sequences. Different recombinant plasmids, pET32a-MBP-DrNDase-EK-HsNST Mut02 and pET32a-MBP-PvNDase EK-HsNST, were obtained. The recombinant plasmids Mut02, pET32a-MBP-DrNDase-G4S-HsNST, Mut02, pET32a-MBP-DrNDase-G6-HsNST, Mut02, pET32a-MBP-DrNDase / HsNST, Mut02, pET32a-MBP-PvNDase / HsNST, Mut02, pET32a-MBP-DrNDase / HsNST WT, and pET32a-MBP-DrNDase / DrNST were transformed into E. coli Rosetta(DE3). Transformants were obtained after cultivation. Positive transformants, verified by sequencing, were identified as recombinant E. coli strains expressing artificial heparan sulfate N-deacetyl / N-sulfotransferase. The cultivation, enzyme induction, and extraction methods for the recombinant E. coli strains were as described in Example 1. The crude enzyme solution was used to detect enzyme activity. The enzyme activation reaction system included an appropriate amount of artificial heparan sulfate N-deacetyl / N-sulfotransferase, 1 mg heparin precursor, 10 mM CaCl2, 50 mM MPNPS, 0.5 mM PAP, 2 mg AST IV, and 10% (v / v) glycerol. The reaction system was brought to a final volume of 1.0 mL with a 20 mM Tris-HCl buffer system (pH 7.5) and incubated at 37 °C for 12–24 h.
[0084] Table 2 Primer Construction
[0085]
[0086] Note: Underlined letters indicate the homologous arm sequence used in homologous recombination.
[0087] The results are as follows Figure 2As shown, the enzyme activity of DrNDase-EK-HsNST Mut02 with the EAAAK linker sequence was 23% higher than that of PvNDase-EK-HsNST Mut02; compared with the one with the linker sequence, the enzyme activity of PvNDase / HsNSTMut02 without the linker sequence was increased by 100%, while the enzyme activity of DrNDase / HsNST Mut02 was increased by at least 156%.
[0088] The effects of different NSTs on artificial bifunctional enzymes were compared. The results showed that the C-terminus of DrNDase linked to unmutated HsNST and DrNST could detect the activity of bifunctional enzymes, but it was far less effective than the mutant HsNSTMut02 with improved enzyme properties.
[0089] Example 3: Construction and analysis of artificial heparan sulfate N-deacetyl / N-sulfotransferase mutants
[0090] To enhance the activity of artificial heparan sulfate N-deacetyl / N-sulfotransferase and meet the synthesis requirements of heparan sulfate and heparin, the recombinant plasmid DrNDase / HsNST Mut02, which exhibits relatively high activity and was constructed in Example 2, was used as a template. Different point mutation primers targeting the DrNDase sequence were designed, and amplification was performed using standard PCR procedures. After digesting the template with the restriction enzyme DpnI, the amplified PCR products were ligated and circularized using the Blunting Kination Ligation kit and transformed into E. coli JM019. Sequencing yielded single mutant proteins D110E, I111V, Q189L, F219H, R224G, E227L, T244S, R255Q, S260I, A269S, N351T, A369T, S385V, I443V, V478I, S480N, S483M, G505S, L512S, S561R, I577L, P579S, R582K, R582V, H585L, D588N, and E591A. These were then transformed into E. coli cells according to the method described in Example 1. The proteins were screened and cultured in Rosetta (DE3), and their enzyme activity was detected according to the method in Example 2. Furthermore, a combined mutant protein was constructed based on the single mutant protein.
[0091] The selected combined mutant proteins were further purified using affinity chromatography, and the protein concentration was detected using the Bradford assay kit. An equal volume of the purified enzyme solution was used for enzyme activity detection, and the enzyme activity was detected according to the method in Example 2.
[0092] Table 3. Mutant Primer Table
[0093]
[0094]
[0095] Note: Underlined letters indicate the homologous arm sequences used during homologous recombination, and bolded parts are the nucleotide sequences corresponding to the mutation sites.
[0096] The results are as follows Figure 3 As shown in figure a, the enzyme activity of F219H / S480N is significantly increased, by 126% compared to the wild type. Figure 3 As shown in b, the enzyme activity of F219H / S480N / R582V was 23% higher than that of its parent.
[0097] Depend on Figure 4 It can be seen that the specific enzyme activity of the combined mutant protein F219H / S480N / R582V reached a maximum of 2812 U / mg, which is 263% higher than that of the initially constructed wild type.
[0098] Example 4: Catalysis of the artificial heparan sulfate N-deacetyl / N-sulfotransferase combined mutant
[0099] The optimal mutant protein combination F219H / S480N / R582V constructed and screened in Example 3 was used for the conversion of N-sulfonated heparin precursor. The enzyme catalytic system included 0.1-2 mg of purified enzyme solution, 200 μg of heparin precursor, 10 mM CaCl2, 50 mM MPNPS, 0.5 mM PAP, 2 mg AST IV, and 10% (v / v) glycerol, with the reaction system adjusted to 1.0 mL using a 20 mM Tris-HCl buffer system (pH 7.5); or, it included an appropriate amount of purified enzyme solution, 200 μg of heparin precursor, 10 mM CaCl2, 4 mM PAPS, 10% (v / v) glycerol, with the reaction system adjusted to 1.0 mL using a 20 mM Tris-HCl buffer system (pH 7.5). 7.5) Adjust the volume of the reaction system to 1.0 mL; after incubating at 37℃ for 12-24 h, add 1 mg of heparin lyase to the reaction system to fully degrade it into disaccharide. Filter the lysate through a 0.22 μm filter membrane and identify and analyze it using ultra-high performance liquid chromatography-tandem quadrupole time-of-flight mass spectrometry.
[0100] The results are as follows Figure 5 a, Figure 5 As shown in b, the combined mutant protein F219H / S480N / R582V has an N-sulfonation conversion rate of over 80% for 200 mg / L heparin precursor and over 60% for 2000 mg / L heparin precursor.
[0101] Although the present invention has been disclosed above with reference to preferred embodiments, it is not intended to limit the present invention. Any person skilled in the art can make various modifications and alterations without departing from the spirit and scope of the present invention. Therefore, the scope of protection of the present invention should be determined by the claims.
Claims
1. A heparan sulfate N-deacetyl / N-sulfotransferase, characterized in that, The heparin sulfate N-deacetyl / N-sulfotransferase is formed by linking heparin sulfate N-deacetylase with the heparin sulfate N-sulfotransferase; The heparin sulfate N-deacetylase is selected from amino acids 41-606 of the zebrafish-derived heparin sulfate N-deacetylase sequence with NCBI accession number NP_001311384.1, amino acids 99-657 of the Litopenaeus vannamei-derived heparin sulfate N-deacetylase sequence with NCBI accession number XP_027233623.1, or amino acids 40-602 of the human-derived heparin sulfate N-deacetylase sequence with NCBI accession number NP_001534.
1. The heparin sulfate N-sulfotransferase is selected from amino acids 607-886 of the zebrafish-derived heparin sulfate N-sulfotransferase sequence with NCBI accession number NP_001311384.1, or human heparin sulfate N-sulfotransferase Mut02 with the amino acid sequence shown in SEQ ID NO.
7.
2. The heparin sulfate N-deacetyl / N-sulfonyltransferase according to claim 1, characterized in that, The N-terminus of the heparin N-deacetyl sulfate enzyme is fused with a maltose-binding protein using a G4S linker peptide; the C-terminus of the heparin N-deacetyl sulfate enzyme is fused with a heparin N-sulfotransferase; optionally, there is no linker sequence between the heparin N-deacetyl sulfate enzyme and the heparin N-sulfotransferase, or an EAAAK, G4S, or G6 linker peptide is used.
3. A mutant protein of heparan sulfate N-deacetyl / N-sulfotransferase, characterized in that, The mutant protein is derived from heparan sulfate N-deacetylase and heparan sulfate N-sulfotransferase, whose amino acid sequences are shown in SEQ ID NO.1, and is subjected to one or more of the following mutations: (1) The heparin sulfate N-deacetyl / N-sulfotransferase mutant protein was obtained by replacing the aspartic acid (D) residue at position 110 with the glutamate (E) residue; (2) The mutant protein of heparan sulfate N-deacetyl / N-sulfotransferase obtained by replacing the isoleucine (I) residue at position 111 with a valine (V) residue; (3) The mutant protein of heparan sulfate N-deacetyl / N-sulfotransferase was obtained by replacing the glutamine (Q) residue at position 189 with a leucine (L) residue; (4) The mutant protein of heparan sulfate N-deacetyl / N-sulfotransferase was obtained by replacing the phenylalanine (F) residue at position 219 with histidine (H) residue; (5) The mutant protein of heparan sulfate N-deacetyl / N-sulfotransferase obtained by replacing the arginine (R) residue at position 224 with a glycine (G) residue; (6) The mutant protein of heparan sulfate N-deacetyl / N-sulfotransferase obtained by replacing the glutamate (E) residue at position 227 with a leucine (L) residue; (7) The mutant protein of heparan sulfate N-deacetyl / N-sulfotransferase obtained by replacing the threonine (T) residue at position 244 with a serine (S) residue; (8) The mutant protein of heparan sulfate N-deacetyl / N-sulfotransferase obtained by replacing the arginine (R) residue at position 255 with a glutamine (Q) residue; (9) The mutant protein of heparan sulfate N-deacetyl / N-sulfotransferase obtained by replacing the serine (S) residue at position 260 with the isoleucine (I) residue; (10) The mutant protein of heparan sulfate N-deacetyl / N-sulfotransferase obtained by replacing the alanine (A) residue at position 269 with a serine (S) residue; (11) The heparin sulfate N-deacetyl / N-sulfotransferase mutant protein was obtained by replacing the asparagine (N) residue at position 351 with a threonine (T) residue; (12) The mutant protein of heparan sulfate N-deacetyl / N-sulfotransferase obtained by replacing the alanine (A) residue at position 369 with a threonine (T) residue; (13) The mutant protein of heparan sulfate N-deacetyl / N-sulfotransferase obtained by replacing the serine (S) residue at position 385 with a valine (V) residue; (14) The mutant protein of heparan sulfate N-deacetyl / N-sulfotransferase obtained by replacing the isoleucine (I) residue at position 443 with a valine (V) residue; (15) The mutant protein of heparan sulfate N-deacetyl / N-sulfotransferase obtained by replacing the valine (V) residue at position 478 with the isoleucine (I) residue; (16) The heparin sulfate N-deacetyl / N-sulfotransferase mutant protein was obtained by replacing the serine (S) residue at position 480 with an asparagine (N) residue; (17) The mutant protein of heparan sulfate N-deacetyl / N-sulfotransferase obtained by replacing the serine (S) residue at position 483 with a methionine (M) residue; (18) The heparin sulfate N-deacetyl / N-sulfotransferase mutant protein was obtained by replacing the glycine (G) residue at position 505 with a serine (S) residue; (19) The mutant protein of heparan sulfate N-deacetyl / N-sulfotransferase obtained by replacing the leucine (L) residue at position 512 with a serine (S) residue; (20) The heparin sulfate N-deacetyl / N-sulfotransferase mutant protein was obtained by replacing the serine (S) residue at position 561 with an arginine (R) residue; (21) The mutant protein of heparan sulfate N-deacetyl / N-sulfotransferase obtained by replacing the isoleucine (I) residue at position 577 with a leucine (L) residue; (22) The heparin sulfate N-deacetyl / N-sulfotransferase mutant protein was obtained by replacing the proline (P) residue at position 579 with a serine (S) residue; (23) The heparin sulfate N-deacetyl / N-sulfotransferase mutant protein obtained by replacing the arginine (R) residue at position 582 with a valine (V) or lysine (K) residue; (24) The mutant protein of heparan sulfate N-deacetyl / N-sulfotransferase obtained by replacing histidine (H) residue at position 585 with leucine (L) residue; (25) The heparin sulfate N-deacetyl / N-sulfotransferase mutant protein was obtained by replacing the aspartic acid (D) residue at position 588 with an asparagine (N) residue; (26) The mutant protein of heparan sulfate N-deacetyl / N-sulfotransferase was obtained by replacing the glutamate (E) residue at position 591 with an alanine (A) residue.
4. The mutant protein according to claim 3, characterized in that... The mutant protein is derived from heparan sulfate N-deacetylase and heparan sulfate N-sulfotransferase, whose amino acid sequences are shown in SEQ ID NO.1, and is subjected to any of the following combination mutations: (a) The phenylalanine (F) residue at position 219 was replaced with a histidine (H) residue, and the serine (S) residue at position 480 was replaced with an asparagine (N) residue, to obtain the combined spike protein F219H / S480N; (b) The phenylalanine (F) residue at position 219 is replaced with a histidine (H) residue, the serine (S) residue at position 480 is replaced with an asparagine (N) residue, and the arginine (R) residue at position 582 is replaced with a valine (V) or lysine (K) residue to obtain the combined spike protein F219H / S480N / R582V or F219H / S480N / R582K.
5. A gene encoding the heparan sulfate N-deacetyl / N-sulfotransferase of claim 1 or 2 or the mutant protein of claim 3 or 4.
6. A recombinant plasmid carrying the gene of claim 5.
7. A recombinant cell expressing the heparan sulfate N-deacetyl / N-sulfotransferase of claim 1 or 2 or the mutant protein of claim 3 or 4, or containing the gene of claim 5, or carrying the recombinant plasmid of claim 6.
8. A recombinant Escherichia coli, characterized in that, The recombinant Escherichia coli uses pET32a vector as the expression vector to express the heparan sulfate N-deacetylase and heparan sulfate N-sulfotransferase as described in claim 1 or 2, or the mutant protein as described in claim 3 or 4.
9. A method for enzyme-catalyzed preparation of N-sulfonated heparin precursor, characterized in that, The method involves using heparin precursor as a substrate and employing the heparin sulfate N-deacetylase and heparin sulfate N-sulfotransferase as described in claim 1 or 2, or the mutant protein as described in claim 3 or 4, as catalysts to form a catalytic system for the synthesis of N-sulfonated heparin precursor.
10. The use of the heparan sulfate N-deacetylase and heparan sulfate N-sulfotransferase as described in claim 1 or 2, or the mutant protein as described in claim 3 or 4, in the synthesis of heparan sulfate, heparin, and low molecular weight heparin and heparin oligosaccharides.
